Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 10

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 10
---
 a group, with the objective of maintaining a Board that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of backgrounds and experiences in various areas. In determining whether to recommend a director for re-election, the Nominating and Corporate Governance Committee also considers the director’s past attendance at meetings,

<div align='center'>6</div>

participation in and contribution to the activities of the Board and the Company and other qualifications and characteristics set forth in the charter of the Nominating and Corporate Governance Committee.

Although our Board does not maintain a specific policy with respect to board diversity, our Board believes that it should be a diverse body, and its Nominating and Corporate Governance Committee considers a broad range of backgrounds and experiences. In making determinations regarding nominations of directors, our Nominating and Corporate Governance Committee may take into account the benefits of diverse viewpoints. Our Board’s Nominating and Corporate Governance Committee also considers these and other factors as it oversees the annual board of director and committee evaluations. After completing its review and evaluation of director candidates, the Nominating and Corporate Governance Committee recommends to our Board the director nominees for selection.

Our corporate governance guidelines also dictate that a majority of the Board be comprised of independent directors whom the Board has determined have no material relationship with the Company and who are otherwise "independent" directors under the published listing requirements of the Nasdaq Capital Market (“Nasdaq”).

#### Director Nominees
The Class II nominees for director along with their biographical information as of April 17, 2025 are set forth below:

| Name                   |     | Age |     | Position(s)                                     |     | Director Since |     | Board Class / Term Expiration |
| Anupam Dalal, M.D.     |     |  53 |     | Director                                        |     |           2011 |     | II - 2028                     |
| Mohammad Hirmand, M.D. |     |  55 |     | Director                                        |     |           2023 |     | II - 2028                     |
| David Lennon, Ph.D.    |     |  54 |     | Director; President and Chief Executive Officer |     |           2023 |     | II - 2028                     |

Anupam Dalal, M.D., has served on our board of directors since November 2011. Since August 2016, Dr. Dalal has been working at Acuta Capital